Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis
NEWTON, Mass., Feb. 23, 2021 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee recommending the use of RELiZORB® (immobilized lipase cartridge), a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. Their recommendation further reinforces the clinical benefits of RELiZORB (immobilized lipase cartridge) in patients with fat malabsorption conditions beyond cystic fibrosis.